Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401595 · ClinicalTrials.gov registry record · Phase 3
Brain Imaging and Treatment Studies of the Night Eating Syndrome
A Phase 3 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT01401595: Completed Phase 3 study, sponsored by University of Pennsylvania.
NCT01401595 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01401595, a Phase 3 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.
Interventions
- DRUG escitalopram oxalate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401595
The ClinicalTrials.gov registry entry for NCT01401595 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which escitalopram oxalate is the first listed.
NCT01401595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401595 about?
NCT01401595 is a clinical study titled "Brain Imaging and Treatment Studies of the Night Eating Syndrome". The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.
What is the current status of trial NCT01401595?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2009-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01401595?
The interventions under investigation include: escitalopram oxalate (DRUG).
Who is sponsoring clinical trial NCT01401595?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.